1460Effect of the INR stability characteristics on bleeding events among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial

Autor: K.A.A Fox, Charles Michael Gibson, Roxana Mehran, Michael X Cohen, Jonathan L. Halperin, T Nafee, M Kerneis, C. Bode, Megan Yee, Eric D. Peterson, R Travis, P Wildegoose, F.W. Verheugt, G Y H Lip, Gerald Chi

Publikováno v: European Heart Journal. 39

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a517baf66a17743b8c7e004ba5d23524
https://doi.org/10.1093/eurheartj/ehy565.1460

P4569Rivaroxaban treatment strategies reduce costs associated with rehospitalizations due to bleeding and cardiovascular events: results from the PIONEER AF-PCI trial

Autor: Michael X Cohen, Peter Wildgoose, Gyh Lip, Jonathan L. Halperin, Charles Michael Gibson, K.A.A Fox, Yazan Daaboul, F.W. Verheugt, Martin van Eickels, Hector Tamez, Serge Korjian, Roxana Mehran, C. Bode, Eric D. Peterson, Duane S. Pinto

Publikováno v: European Heart Journal. 38

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ae298e52720fd8a200d751d0685f0be
https://doi.org/10.1093/eurheartj/ehx504.p4569

P3590Rivaroxaban strategies improve the number of days patients remain out of the hospital and event free: A PIONEER substudy

Autor: Martin van Eickels, G Y H Lip, Yazan Daaboul, Michael X Cohen, Jonathan L. Halperin, F.W. Verheugt, Serge Korjian, Purva Jain, C. Bode, Douglas Arbetter, Roxana Mehran, Charles Michael Gibson, Peter Wildgoose, K.A.A Fox, Eric D. Peterson

Publikováno v: European Heart Journal. 38

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8fd6d247b6b46febae2c447fb0a167c2
https://doi.org/10.1093/eurheartj/ehx504.p3590

Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial

Autor: A. W. J. van ’t Hof, B. Backx, M. van Eickels, F.W. Verheugt, Jacques J. Koolen, Pascal Vranckx, Frank W.G. Leebeek, F. Stammen, Frank Misselwitz, J. G. P. Tijssen, Bodo Kirsch, Stephen Kim, R. J. de Winter, W. Lindeboom, J.-P. R. Herman

Publikováno v: Thrombosis and Haemostasis, 114, 2, pp. 258-67
Thrombosis and Haemostasis, 114, 258-67
Thrombosis and Haemostasis, 114(2), 258-267. Georg Thieme Verlag
Thrombosis and haemostasis, 114(2), 258-267. Schattauer GmbH

SummaryPatients on rivaroxaban requiring percutaneous coronary intervention (PCI) represent a clinical conundrum. We aimed to investigate whether rivaroxaban, with or without an additional bolus of unfractionated heparin (UFH), effectively inhibits c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5908b947ea5f0e6bd82ee03579121730
https://hdl.handle.net/2066/153620

Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA

Autor: NL Fox, Xuri Li, Paul W. Armstrong, Hal V. Barron, Christopher B. Granger, F.W. Verheugt, Robert M. Califf, G I Barbash, Kenneth Pehrsson, S Berioli, F. Van de Werf, Amadeo Betriu, Jürgen Meyer

Publikováno v: European Heart Journal, 22, 2253-61
European Heart Journal, 22, 24, pp. 2253-61

Item does not contain fulltext BACKGROUND: Fibrinolytic therapy increases the risk of bleeding events. TNK-tPA (tenecteplase) is a variant of rt-PA with greater fibrin specificity and reduced plasma clearance that can be given as a single bolus. We c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ceb7e3fd302757802327920fbb371a
https://pubmed.ncbi.nlm.nih.gov/11728139